Dashboard
Manage Tickers

ATOS ATOSSA THERAPEUTICS, INC.

Nasdaq atossatherapeutics.com


$ 0.81 $ -0.02 (-2.46 %)    

Wednesday, 12-Nov-2025 12:05:05 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 619.51 $ -5.27 (-0.84 %)
DIA $ 483.11 $ 2.55 (0.53 %)
SPY $ 682.40 $ -2.39 (-0.34 %)
TLT $ 90.24 $ 0.29 (0.32 %)
GLD $ 386.22 $ 6.04 (1.59 %)
$ 0.8277
$ 0.84
$ 0.80 x 60
$ 0.81 x 100
$ 0.80 - $ 0.85
$ 0.55 - $ 1.62
236,223
na
106.92M
$ 1.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-25-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-13-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-28-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-14-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-12-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atossa-therapeutics-q3-eps-007-inline
Atossa Therapeutics Q3 EPS $(0.07), Inline
11/12/2025 13:18:14

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This...

atossa-therapeutics-to-present-four-abstracts-on-z-endoxifen-at-san-antonio-breast-cancer-symposium
Atossa Therapeutics To Present Four Abstra...
11/06/2025 13:31:40

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical compan...

atossa-highlights-enrollment-progress-and-biomarker-strategy-for-recast-trial-aiming-to-de-risk-development-of-z-endoxifen-for-ductal-carcinoma-in-situ
Atossa Highlights Enrollment Progress And ...
10/21/2025 12:17:57

Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk de...

atossa-therapeutics-appoints-mark-daniel-as-cfo
Atossa Therapeutics Appoints Mark Daniel A...
10/14/2025 12:15:09

25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience...

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-775
Ascendiant Capital Maintains Buy on Atossa...
09/22/2025 09:28:37

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-announces-it-has-requested-a-type-c-meeting-with-the-fda-to-discuss-a-regulatory-strategy-to-accelerate-the-development-of-low-dose-endoxifen-for-reducing-breast-cancer-risk
Atossa Therapeutics Announces It Has Reque...
09/08/2025 12:36:20

Atossa Therapeutics, Inc. (NASDAQ:ATOS, ", Atossa", or the ", Company", ))) announced today it has requested a ...

atossa-therapeutics-selects-psi-to-manage-fda-guided-z-endoxifen-dose-ranging-study-in-metastatic-breast-cancer-ahead-of-phase-3
Atossa Therapeutics Selects PSI To Manage ...
08/20/2025 12:31:56

Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025Topline results anticipated in 2026 Positions Atossa ...

atossa-therapeutics-q2-eps-007-misses-006-estimate
Atossa Therapeutics Q2 EPS $(0.07) Misses ...
08/12/2025 12:38:44

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...

atossa-therapeutics-announces-fda-feedback-on-proposed-dose-optimization-trial-of-z-endoxifen-clinical-program-in-erher2--metastatic-breast-cancer
Atossa Therapeutics Announces FDA Feedback...
07/29/2025 11:46:15

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-75
Ascendiant Capital Maintains Buy on Atossa...
06/06/2025 10:40:29

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

this-excelerate-energy-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Excelerate Energy Analyst Begins Cove...
06/05/2025 19:17:32

craig-hallum-initiates-coverage-on-atossa-therapeutics-with-buy-rating-announces-price-target-of-4
Craig-Hallum Initiates Coverage On Atossa ...
06/05/2025 17:15:59

Craig-Hallum analyst Albert Lowe initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Pri...

atossa-therapeutics-reports-full-results-from-phase2-eop-substudy-within-ispy2-trial-evaluating-lowdose-oral-zendoxifen-as-neoadjuvant-treatment-in-20-women-with-stageiiiii-er-her2negative-breast-cancer
Atossa Therapeutics Reports Full Results F...
05/14/2025 12:19:03

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable sa...

atossa-therapeutics-q1-eps-005-beats-006-estimate
Atossa Therapeutics Q1 EPS $(0.05) Beats $...
05/13/2025 12:06:38

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-awarded-us-patent-no-12281056-including-58-claims-covering-various-formulations-for-its-z-endoxifen-portfolio
Atossa Therapeutics Awarded U.S. Patent No...
04/30/2025 12:49:50

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...

atossa-therapeutics-outlines-framework-for-pioneering-phase-3-clinical-study-titled-smart-20-at-aacr-2025
Atossa Therapeutics Outlines Framework For...
04/29/2025 12:52:23

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...

atossa-therapeutics-uspto-grants-new-patent-directed-to-enteric-oral-formulations-comprising-z-endoxifen-as-well-as-methods-of-treating-subjects-with-oral-formulations
Atossa Therapeutics: USPTO Grants New Pate...
04/22/2025 12:46:52

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company")...

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-725
Ascendiant Capital Maintains Buy on Atossa...
04/21/2025 10:08:07

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-files-petition-for-post-grant-review-against-company-intas-pharmaceuticals-files-petition-for-inter-partes-review-against-company-to-contest-pgr-and-lpr-petitions
Atossa Therapeutics Files Petition For Pos...
04/07/2025 20:21:21

-SEC Filing

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
03/26/2025 10:03:51

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $7 price ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION